SciSparc Flags Going Concern Doubt as Cash Runs Short
SPRC sits 58% above its 52-week low of $2.98 on light trading volume (0.1× avg).
Summary
SciSparc's H1 2026 report warns it may not survive a year on current cash, while the CliniQ acquisition diluted its NeuroThera stake from 75% to 43.86%.
Key Events · Earnings and Guidance · SPRC
-
Going Concern Warning
Cash of $4.4M is insufficient to fund planned operations for at least a year beyond the filing date; management cites substantial doubt about continuing as a going concern.
-
H1 2026 Net Loss
Net loss of $6.05M for the six months ended June 30, 2026, with negative working capital of $1.37M and an accumulated deficit of $92.5M.
-
CliniQ Transaction Dilution
NeuroThera's June 3 acquisition of 54.01% of CliniQuantum reduced SciSparc's stake in NeuroThera from 75% to 43.86%, adding a $2.5M earn-out liability.
-
Convertible Note Financing
February 2026 note: $2M principal issued for $1.8M, with 3,651,554 warrants at $4.9294 exercise price; up to $10M total available under the SPA.
Analysis · SPRC · Life Sciences
The H1 2026 interim report from SciSparc carries a formal going concern warning: with only $4.4M in cash, the company cannot fund operations for at least a year beyond the filing date. A net loss of $6.05M over six months and an accumulated deficit of $92.5M underscore the strain. The filing also details the June 3 CliniQ Transaction, which diluted SciSparc's stake in NeuroThera from 75% to 43.86% and added a $2.5M earn-out liability. Against a market cap of roughly $2.7M, the survival risk dominates the narrative.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 46% of the 298 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRC was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $2.98 to $63.90. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.